R&G PharmaStudies Future Growth
Future criteria checks 3/6
R&G PharmaStudies is forecast to grow earnings and revenue by 21.2% and 18.7% per annum respectively. EPS is expected to grow by 13.6% per annum. Return on equity is forecast to be 11.7% in 3 years.
Key information
21.2%
Earnings growth rate
13.6%
EPS growth rate
Life Sciences earnings growth | 30.4% |
Revenue growth rate | 18.7% |
Future return on equity | 11.7% |
Analyst coverage | Low |
Last updated | 23 Apr 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,248 | 274 | N/A | 285 | 1 |
12/31/2025 | 1,045 | 234 | N/A | 251 | 3 |
12/31/2024 | 863 | 175 | N/A | 162 | 2 |
3/31/2024 | 738 | 157 | 177 | 198 | N/A |
12/31/2023 | 721 | 163 | 173 | 193 | N/A |
9/30/2023 | 711 | 154 | 163 | 186 | N/A |
6/30/2023 | 673 | 138 | 106 | 128 | N/A |
3/31/2023 | 628 | 116 | 126 | 144 | N/A |
1/1/2023 | 638 | 113 | 110 | 130 | N/A |
9/30/2022 | 634 | 112 | 121 | 154 | N/A |
6/30/2022 | 640 | 110 | 93 | 127 | N/A |
3/31/2022 | 632 | 101 | 66 | 102 | N/A |
1/1/2022 | 608 | 99 | 76 | 115 | N/A |
12/31/2020 | 484 | 84 | 19 | 44 | N/A |
12/31/2019 | 425 | 83 | 77 | 103 | N/A |
12/31/2015 | 142 | 24 | N/A | 17 | N/A |
12/31/2014 | 96 | 14 | N/A | 24 | N/A |
12/31/2013 | 78 | 12 | N/A | 10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301333's forecast earnings growth (21.2% per year) is above the savings rate (2.9%).
Earnings vs Market: 301333's earnings (21.2% per year) are forecast to grow slower than the CN market (24.1% per year).
High Growth Earnings: 301333's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301333's revenue (18.7% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 301333's revenue (18.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 301333's Return on Equity is forecast to be low in 3 years time (11.7%).